Get the Stockscreener App
938.81
1.82%
-16.38
Overview
News
Price History
Option Chain
Financials
Why LLY Down?
Discussions
Forecast
Stock Split
Dividend History
Lilly Eli Co stock is traded at $938.81, with a volume of 1.05M.
It is down -1.82% in the last 24 hours and down -6.35% over the past month.
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.
See More
Previous Close:
$955.19
Open:
$963.69
24h Volume:
1.05M
Relative Volume:
0.34
Market Cap:
$838.67B
Revenue:
$65.18B
Net Income/Loss:
$20.64B
P/E Ratio:
41.56
EPS:
22.5894
Net Cash Flow:
$5.96B
1W Performance:
+0.24%
1M Performance:
-6.35%
6M Performance:
+12.51%
1Y Performance:
+30.08%
1-Day Range:
$935.87
$963.94
1-Week Range:
$898.45
$963.94
52-Week Range:
$623.78
$1,133.95
Lilly Eli Co Stock (LLY) Company Profile
Name
Lilly Eli Co
Sector
Industry
Phone
(317) 276-2000
Address
LILLY CORPORATE CTR, INDIANAPOLIS, IN
Compare LLY vs JNJ, ABBV, AZN, MRK
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
LLY
Lilly Eli Co
|
938.78 | 853.33B | 65.18B | 20.64B | 5.96B | 22.59 |
JNJ
Johnson Johnson
|
238.38 | 581.22B | 94.19B | 26.80B | 19.70B | 11.05 |
ABBV
Abbvie Inc
|
209.15 | 375.69B | 61.16B | 4.19B | 17.82B | 2.3614 |
AZN
Astrazeneca Plc
|
204.55 | 317.91B | 58.80B | 10.24B | 8.98B | 3.2788 |
MRK
Merck Co Inc
|
121.36 | 303.00B | 64.93B | 18.26B | 12.36B | 7.2751 |
Lilly Eli Co Stock (LLY) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-17-26 | Downgrade | HSBC Securities | Hold → Reduce |
| Feb-25-26 | Initiated | RBC Capital Mkts | Outperform |
| Feb-20-26 | Initiated | Barclays | Overweight |
| Jan-07-26 | Resumed | UBS | Buy |
| Dec-16-25 | Upgrade | Daiwa Securities | Neutral → Buy |
| Dec-15-25 | Reiterated | BofA Securities | Buy |
| Dec-15-25 | Reiterated | Goldman | Buy |
| Nov-13-25 | Initiated | Scotiabank | Sector Outperform |
| Nov-10-25 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Oct-20-25 | Reiterated | BMO Capital Markets | Outperform |
| Oct-14-25 | Upgrade | Erste Group | Hold → Buy |
| Sep-17-25 | Downgrade | Berenberg | Buy → Hold |
| Aug-27-25 | Upgrade | HSBC Securities | Reduce → Hold |
| Aug-18-25 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Aug-07-25 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Jun-05-25 | Downgrade | Erste Group | Buy → Hold |
| Apr-28-25 | Downgrade | HSBC Securities | Buy → Reduce |
| Apr-22-25 | Initiated | Cantor Fitzgerald | Overweight |
| Dec-10-24 | Resumed | BofA Securities | Buy |
| Nov-15-24 | Initiated | Wolfe Research | Outperform |
| Oct-17-24 | Initiated | Bernstein | Outperform |
| Sep-13-24 | Resumed | Citigroup | Buy |
| Aug-12-24 | Upgrade | Deutsche Bank | Hold → Buy |
| Feb-21-24 | Downgrade | DZ Bank | Buy → Hold |
| Feb-16-24 | Reiterated | Morgan Stanley | Overweight |
| Dec-21-23 | Downgrade | Daiwa Securities | Buy → Outperform |
| Nov-09-23 | Initiated | Deutsche Bank | Hold |
| Oct-20-23 | Resumed | UBS | Buy |
| Aug-09-23 | Upgrade | Jefferies | Hold → Buy |
| Jul-26-23 | Reiterated | Citigroup | Buy |
| Jul-14-23 | Initiated | HSBC Securities | Buy |
| May-24-23 | Reiterated | BofA Securities | Buy |
| May-24-23 | Reiterated | UBS | Buy |
| Mar-13-23 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Mar-06-23 | Initiated | Jefferies | Hold |
| Feb-15-23 | Downgrade | Societe Generale | Hold → Sell |
| Nov-18-22 | Initiated | Credit Suisse | Outperform |
| Sep-22-22 | Upgrade | UBS | Neutral → Buy |
| May-23-22 | Initiated | SVB Leerink | Outperform |
| Apr-06-22 | Resumed | Morgan Stanley | Overweight |
| Mar-10-22 | Initiated | Daiwa Securities | Outperform |
| Jan-21-22 | Upgrade | DZ Bank | Hold → Buy |
| Jan-03-22 | Reiterated | Bernstein | Mkt Perform |
| Dec-17-21 | Initiated | Goldman | Neutral |
| Dec-16-21 | Reiterated | BMO Capital Markets | Outperform |
| Dec-16-21 | Reiterated | BofA Securities | Buy |
| Dec-09-21 | Resumed | Wells Fargo | Equal Weight |
| Nov-19-21 | Initiated | BMO Capital Markets | Outperform |
| Oct-11-21 | Upgrade | Berenberg | Hold → Buy |
| Sep-29-21 | Upgrade | Citigroup | Neutral → Buy |
| Aug-05-21 | Upgrade | DZ Bank | Hold → Buy |
| Jul-27-21 | Resumed | Truist | Buy |
| Jun-24-21 | Reiterated | Cantor Fitzgerald | Overweight |
| Jan-19-21 | Upgrade | Mizuho | Neutral → Buy |
| Dec-10-20 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Nov-10-20 | Resumed | Bernstein | Mkt Perform |
| Sep-29-20 | Initiated | Berenberg | Hold |
| Sep-03-20 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Jun-16-20 | Upgrade | Guggenheim | Neutral → Buy |
| Apr-21-20 | Downgrade | UBS | Buy → Neutral |
| Apr-09-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Feb-06-20 | Initiated | Mizuho | Neutral |
| Dec-18-19 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Oct-17-19 | Resumed | BofA/Merrill | Buy |
| May-28-19 | Initiated | Goldman | Buy |
| Apr-24-19 | Upgrade | Edward Jones | Hold → Buy |
| Apr-11-19 | Downgrade | Guggenheim | Buy → Neutral |
| Mar-12-19 | Initiated | JP Morgan | Overweight |
| Jan-23-19 | Initiated | UBS | Buy |
| Nov-26-18 | Downgrade | Citigroup | Buy → Neutral |
| Oct-31-18 | Upgrade | Credit Suisse | Underperform → Neutral |
| Oct-09-18 | Initiated | Guggenheim | Buy |
| Oct-01-18 | Reiterated | SunTrust | Buy |
| Sep-26-18 | Resumed | JP Morgan | Overweight |
View All
Lilly Eli Co Stock (LLY) Latest News
Eli Lilly (LLY) Expands Patient Access to Foundayo for Weight Ma - GuruFocus
RBC Capital reiterates Eli Lilly stock rating on GLP-1 strength - Investing.com
LifeMD adds Eli Lilly’s oral weight loss drug to platform By Investing.com - Investing.com India
Amazon Pharmacy to offer Eli Lilly’s Foundayo via same-day delivery - Yahoo Finance
Eli Lilly loses weight loss drug market share as generics flood India - qz.com
LifeMD® Now Offering Eli Lilly and Company’s Foundayo™ (orforglipron), a New GLP-1 Pill for Weight Management - The Manila Times
Who Benefits From Amazon Pharmacy Stocking Eli Lilly’s New Weight Loss Pill - 24/7 Wall St.
A new weight-loss pill hits LifeMD, starting at $149 a month - Stock Titan
RBC Capital Maintains Eli Lilly and Co(LLY.US) With Buy Rating, Maintains Target Price $1,250 - 富途牛牛
Lilly to acquire Centessa in deal worth up to $7.8bn - PMLiVE
Top 12 Pharma Companies: Eli Lilly Shoots To The Top, Merck Tumbles - Citeline News & Insights
Atopic Dermatitis (7MM) Drug Market Forecast and Analysis Report 2023-2033: Opportunities Remain for the Treatment of AD, Novel Systemic Therapies Dominate the Late-stage Pipeline - GlobeNewswire Inc.
Eli Lilly Expands Foundayo Obesity Launch As Valuation Signals Upside Potential - simplywall.st
Eli Lilly's proposal to acquire Orna Therapeutics sparks Australian review - MLex
Rep. Gilbert Ray Cisneros, Jr. Sells Eli Lilly Shares - National Today
Amazon to sell Eli Lilly's new weight-loss pill via kiosks, home delivery - IndyStar
UBS offers $3.094M Autocallable Notes linked to Lilly | AMUB Prospectus Summary - Stock Titan
Amazon Offers Same-Day Delivery of Eli Lilly’s (LLY) Weight-Loss Pill - TipRanks
Amazon Pharmacy to Offer Eli Lilly and Company’s New GLP-1 Pill Foundayo via Same-Day Delivery - Business Wire
Eli Lilly Stock in Focus -- New Pill Launch Challenges Novo Nordisk - GuruFocus
Lilly weight-loss pill Foundayo now available in United States - Inside INdiana Business
Amazon (AMZN.US) Pharmacy introduces Eli Lilly and Co's (LLY.US) weight-loss oral medication, with same-day delivery available in over 3,000 cities. - 富途牛牛
Amazon Pharmacy adds same-day delivery for Eli Lilly's Foundayo weight-loss pill - qz.com
Eli Lilly Launches Foundayo Weight-Loss Pill. What It Means for the Stock. - Barron's
Amazon to stock Lilly's new weight-loss pill at US kiosks, offer same-day delivery - Reuters
Lobbying Update: $30,000 of TIBER CREEK HEALTH STRATEGIES INC. ON BEHALF OF ELI LILLY AND COMPANY lobbying was just disclosed - Quiver Quantitative
Amazon expands access to weight-loss pill with kiosks, same-day delivery - WTHR
GoodRx Expands Access to Eli Lilly's New Diabetes Medications - National Today
Amazon Pharmacy offers Eli Lilly’s GLP-1 pill Foundayo via Same-Day Delivery - Drug Store News
Eli Lilly's New Weight-Loss Pill Foundayo Hits U.S. Pharmacies - National Today
Eli Lilly Just Launched Its $149 Obesity Pill - Benzinga
GoodRx and Eli Lilly Partner to Expand Access to Foundayo and Zepbound KwikPen - Pharmaceutical Commerce
Eli Lilly launches oral GLP-1 drug across US through Lilly Direct, telehealth providers - Fierce Healthcare
Lilly launches GLP-1 pill, kicking off showdown with Novo Nordisk - BioPharma Dive
What to Expect From Eli Lilly's Next Quarterly Earnings Report - Yahoo Finance
GoodRx Expands Access to Eli Lilly and Company’s New Oral GLP-1, Foundayo™, and Zepbound® KwikPen® w - PharmiWeb.com
Global Weight Loss and Obesity Management Market | 12.8% CAGR Growth Trajectory | Asia Pacific, North America Lead | Novo Nordisk, Eli Lilly, Medtronic Drive Integrated Care Evolution - PR Newswire UK
Jim Cramer Reveals Why Eli Lilly (LLY) Will Dominate the Weight Loss Race - Insider Monkey
Eli Lilly (LLY) Partners with Amazon Pharmacy to Distribute New Obesity Medication - GuruFocus
Eli Lilly Vs. Amgen: Who Leads Obesity And IMIDs (NASDAQ:AMGN) - Seeking Alpha
Weight Watchers stock jumps on new Eli Lilly GLP-1 offering By Investing.com - Investing.com South Africa
Eli Lilly Stock in 2026: FDA Approval, GLP-1 Momentum, and a 44% Valuation Upside - TIKR.com
Eli Lilly Navigates a Pivotal Quarter with New Pill and Major Deal - AD HOC NEWS
Weight Watchers stock jumps on new Eli Lilly GLP-1 offering - Investing.com UK
Weight Watchers adds a once-daily weight-loss pill through LillyDirect - Stock Titan
Amazon to sell Eli Lilly’s weight loss pill via same day delivery - Seeking Alpha
What's Going On With GoodRx Stock Thursday? - Benzinga
Amazon Pharmacy begins offering Eli Lilly’s Foundayo medication - Investing.com
Amazon Pharmacy begins offering Eli Lilly’s Foundayo medication By Investing.com - Investing.com India
Eli Lilly Weight-Loss Pill Becomes Available in U.S. - WSJ
AI Models Split on Eli Lilly: Strong Fundamentals, Valuation and Momentum Drive an 11-Point Score Gap - TipRanks
Lilly Eli Co Stock (LLY) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.23%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):